Flagship Biosciences to demonstrate how its Computational Tissue Analysis platform advances clinical pipeline development at the Annual Meeting of the American Society of Clinical Oncology

Monday, May 15, 2017

Visit ASCO booth 25115 to learn more about Flagship’s decision support solutions.  

PharmaJet receives 2017 Innovation Award in Biosciences

Thursday, May 11, 2017

GOLDEN, Colo. – May 11, 2017 – PharmaJet® Inc., the maker of needle-free injection technology, announced today that it received the 2017 Innovation Award in Biosciences. The award, part of the Colorado Manufacturing Awards, recognized the company for their innovation in manufacturing and teamwork, particularly in their participation in the effort to eradicate Polio. 

Pathways Bioscience Announces National Institutes of Health NIDCR SBIR Phase I Award to Develop Potential Oral Mucositis Treatment by Nrf2 Activation

Tuesday, May 09, 2017

Pathways Bioscience, LLC announced today that the National Institute of Dental and Craniofacial Research (NIDCR) has awarded the Company a Small Business Innovation Research (SBIR) Phase I grant to pursue research and development of its PB201 topical formulation for use against oral mucositis, a common cancer therapy side effect that impacts hundreds of thousands of patients in the US each year. PB201 activates the Nuclear Factor, Erythroid 2 Like 2 (NFE2L2, also known as Nrf2) transcription factor pathway, which regulates the expression of a large group of cell protective and anti-inflammatory genes. 

Cetya Therapeutics Announces Seed Round Financing

Monday, May 08, 2017

$220,000 Round includes Canadian firm InSynchrony Ventures Inc Proceeds will advance oncology drug development 

Array BioPharma enters clinical trial collaboration with Merck to evaluate drug combo for colorectal cancer

Monday, May 08, 2017

Array BioPharma and Merck agreed to carry out a clinical trial combining Array’s oral MEK inhibitor binimetinib with Merck’s anti-programmed cell death protein 1 (anti-PD-1) therapy Keytruda®(pembrolizumab) in patients with metastatic colorectal cancer (CRC) with microsatellite stable tumors (MSS CRC). The proposed Merck-sponsored trial, which is projected to start during the second half of 2017, will be designed to establish dosing for the combination therapy, as well as explore the potential antitumor activity of a number of treatment regimens. No financial details were disclosed. 

Cliexa selected as one of 7 healthcare startups at Venture Hall Accelerator Summer Program in Portland, ME

Friday, May 05, 2017

Portland startup accelerator Venture Hall announced Thursday that seven companies from across the country have been selected for the inaugural class of its summer accelerator program offered in partnership with MaineHealth and Unum. 

Servier and miRagen extend collaboration for the research, development and commercialization of microRNA-targeting therapeutics

Wednesday, May 03, 2017

A new program targeting microRNA-92 for the treatment of cardiovascular disease and certain other vascular flow related diseases may support regenerative therapy